According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical business. It concentrates on discovering and also establishing small molecule medicine candidates to treat cancer. The Business‘s items under various stages of advancement include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and also Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “
Numerous various other equities research experts additionally just recently talked about the firm. Noble Financial reissued a “get” rating as well as issued a $11.00 price objective on shares of Onconova Therapeutics in a record on Thursday, September 23rd. Guggenheim dropped their rate target on Onconova Therapeutics from $29.00 to $12.00 as well as established a “get” ranking on the stock in a research note on Tuesday, September 28th.
NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and a twelve month high of $28.95. The business has a 50 day relocating typical rate of $2.90 and a two-hundred day moving average rate of $4.16. The company has a market cap of $46.76 million, a P/E ratio of -1.82 and also a beta of 1.67.
Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly profits results on Thursday, November 11th. The biopharmaceutical company reported ($ 0.22) revenues per share for the quarter, topping analysts’ consensus estimates of ($ 0.33) by $0.11. Onconova Therapeutics had an adverse return on equity of 59.78% and a negative web margin of 8,294.27%. The firm had profits of $0.06 million during the quarter, contrasted to the agreement estimate of $0.06 million. During the exact same quarter in the prior year, the company posted ($ 0.45) EPS. As a group, research analysts anticipate that Onconova Therapeutics will upload -1.18 EPS for the present year.
A number of hedge funds have recently dealt shares of ONTX. GSA Funding Allies LLP bought a new placement in Onconova Therapeutics throughout the 3rd quarter worth $922,000. Hudson Bay Resources Administration LP purchased a new placement in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC got a brand-new placement in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC got a brand-new setting in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Lastly, Dimensional Fund Advisors LP got a new placement in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds and various other institutional capitalists possess 13.36% of the firm’s stock.
Regarding Onconova Therapeutics
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical firm, which engages in the recognition and also growth of oncology therapeutics. It concentrates on discovering as well as establishing little particle drug prospects to treat cancer. The firm was founded by Ramesh Kumar and also E. Premkumar Reddy on December 22, 1998 and also is headquartered in Newtown, PA
. Obtain a complimentary copy of the Zacks research record on Onconova Therapeutics (ONTX).
To find out more concerning research offerings from Zacks Investment Research, visit Zacks.com.
This immediate information alert was produced by narrative science innovation as well as financial information from Market in order to give readers with the fastest and most exact coverage. This story was examined by Market’s editorial team prior to magazine.
SHOULD YOU SPEND $1,000 IN ONCONOVA THERAPEUTICS NOW?
Prior to you consider Onconova Therapeutics, you’ll wish to hear this.
Market keeps an eye on Wall Street’s premier and finest performing research experts and the stocks they advise to their clients every day. Market has identified the 5 stocks that cover experts are silently murmuring to their customers to purchase now prior to the wider market catches on … and also Onconova Therapeutics had not been on the list.
While Onconova Therapeutics presently has a “Buy” score among analysts, top-rated analysts believe these 5 stocks are better gets.